Navigation Links
Teikoku Pharma USA Acquires Travanti Pharma Inc.
Date:5/8/2009

SAN JOSE, Calif., May 8 /PRNewswire/ -- Teikoku Pharma USA Inc., the international specialty pharmaceutical company today announced that it has acquired effective May 8, 2009; Minneapolis area based Travanti Pharma Inc., a privately held corporation that designs, develops and markets innovative drug delivery platforms that improve the safety, compliance, effectiveness and ease of administration of medications delivered to the body.

The Company has developed a proprietary Wearable Electronic Disposable Drug delivery technology (WEDD(R)) Platform. WEDD is an innovative electronic transdermal (iontophoretic) drug delivery system that is totally self-contained, single-use, portable and disposable. The company has a number of ready to partner clinical projects focused on improving the delivery of therapeutic medications.

The acquisition is part of Teikoku's core strategy to develop transdermal pharmaceutical products by applying drug delivery technology to make administration of medicines safer and/or more effective, more controllable, and in some cases eliminating the need for injection.

"The acquisition of Travanti Pharma broadens Teikoku's Transdermal delivery capabilities and enhances Teikoku pipelines in the areas of pain and CNS," said Masahisa Kitagawa, President and CEO.

"We are very pleased to join forces with Teikoku, a company that understands our business well and has the capabilities to help move several excellent products based upon Travanti's WEDD technology into the marketplace," commented Robert Cohen, President & CEO of Travanti Pharma. "It is gratifying to complete a transaction that benefits Teikoku, as well as Travanti's shareholders and employees."

About Teikoku

Teikoku Pharma USA Inc., a wholly-owned subsidiary of Teikoku Seiyaku Inc. of Japan, is a specialty pharmaceutical company that develops, and manufactures enhanced pharmaceutical products based on its transdermal drug delivery technologies. Teikoku focuses its efforts in two therapeutic areas; Pain Management and CNS. Teikoku's main product is Lidoderm(R) (Lidocaine 5% Patch) for PHN, in collaboration with Endo Pharmaceuticals in the US, Grunenthal GmbH in Europe, Mundipharma in South East Asia and SK Pharma for Korea.

Teikoku's commitment is to expand transdermal technologies for the benefit of patients and partners. For more information, please visit www.teikokuusa.com


'/>"/>
SOURCE Teikoku Pharma USA Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Teikoku Pharma USA and Eisai Co., Ltd. Announce Licensing Agreement for a New 7-Day Transdermal Formulation of Donepezil.
2. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
3. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
9. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
10. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... CA (PRWEB) , ... February 27, 2017 , ... ... for hair transplantation therapy, is proud to announce a new informational post on ... therapy procedures. Follicular Unit Extraction (FUE) hair transplant and Follicular Unit Transplantation (FUT) ...
(Date:2/26/2017)... (PRWEB) , ... February 26, 2017 , ... ... in 2011 the lab became the world’s first to be ISO/IEC 17025:2005 INAB ... (cat allergen) analysis. , ISO/IEC 17025:2005 is the globally recognised standard that sets ...
(Date:2/26/2017)... ... February 26, 2017 , ... ODH, Inc.™ announced today ... 27-28 at the Sheraton Pentagon City Hotel in Arlington, VA. ODH’s director of medical ... behavioral health analytics to improve Medicaid population health management. , ODH will also have ...
(Date:2/24/2017)... ... 2017 , ... Houston dentist , Dr. Behzad Nazari, ... Center. Currently, patients can get single dental implants for $3,599 and All On ... more about these offers by contacting Antoine Dental Center. Both of these options ...
(Date:2/24/2017)... ... ... The Smart Machine Age is here, and it’s disrupting everything. Not only ... jobs in the United States may be taken over by technology in the next ... who steamrolls over colleagues is drawing to a close. Success will belong to those ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... -- Leading Countries, Technologies and Companies ... at a CAGR of 8.9% from 2016-2021 and CAGR of 9.2% ... of 9.1% from 2016 to 2027. The market is estimated at ... ... Read on to discover how you can exploit the future business ...
(Date:2/27/2017)... Israel , Feb. 27, 2017 ... of adult stem cell technologies for neurodegenerative diseases, announced ... M.D., Ph.D., FACP, and Arturo O. Araya , ... "Dr. Almenoff and Mr. Araya are talented and ... time for our company," said Chaim Lebovits , ...
(Date:2/27/2017)... , Feb 27, 2017 The ... by NATO for use at the security level RESTRICTED. The ... the NATO organization for the communication of classified information. ... Sectra and ... with an eavesdrop-secure smartphone solution. Sectra Tiger/R is developed by ...
Breaking Medicine Technology: